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toward suicide prevention.METHODS: Suicide prevention (SAVE or “guide”) train-
ingwas implemented nationwide starting in 2007. All employees that interact with
patientsmust take the 1-hour instructor-led class consisting of videos, worksheets
and discussion regarding suicide statistics, suicide risk factors, and the responsi-
bility of all VA employees to recognize suicide risk and to intervenewith patients in
distress, including taking an urgently distressed patient by the hand and walking
him from the outpatient pharmacy to the emergency room, for example. At the end
of training, employees completed surveys about attitudes and knowledge of sui-
cide and her role in prevention with Likert scales (range1 to 5). Descriptive sta-
tistics and generalized linear models (GLM) were used to assess differences in
pharmacy staff knowledge and attitudes before and after training and to compare
pharmacy staff to all employees. RESULTS: 7,431 employees from 251 VA Medical
Centers trained January 1- September 30, 2008, including 290 pharmacists, phar-
macy residents and pharmacy staff. At baseline, compared to all employees, phar-
macy staff reported lower levels of suicide knowledge (22% cf. 31%), comfort in
talking about suicide (43% cf. 59%), and being prepared to handle suicidal veterans
(10% cf. 28%). Pharmacists and pharmacy staff improved significantly on every
measure (p0.0001) by the end of training.We found no differences between phar-
macists and other pharmacy staff. After training when given the statement “I
completely agree that I am prepared to handle a suicidal veteran,” women and
those with additional suicide prevention training were most likely to agree while
men and older employees were least likely to do so. CONCLUSIONS: Pharmacists
and pharmacy staff may have greater baseline needs for training in suicide pre-
vention than other staff.
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OBJECTIVES: Psychotherapy has been recommended to be used in conjunction
with pharmacotherapy for the treatment of bipolar disorder. This study examined
the prescribing patterns of the combination of psychotherapy and pharmacother-
apy to treat bipolar disorder in patients receiving outpatient care in the United
States.METHODS:Data from 2006–2007 National Ambulatory Medical Care Survey
(NAMCS) and the outpatient department of National Hospital Ambulatory Medical
Care Survey (NHAMCS) were combined to analyze treatment patterns for bipolar
disorder. Descriptive statistics was used to examine demographic as well as the
clinical characteristics of patients’ visits and the utilization pattern of psychother-
apy in combination with several psychotropic medications. RESULTS: Bipolar dis-
order was diagnosed in 6.09 million annualized outpatient visits in 2006-2007, rep-
resenting 0.29% of the overall visits. Most of the visits weremade by females (66%),
whites (91%) and non-Hispanics (94%). Psychiatric comorbidities such as anxiety
disorders, attention-deficit/ hyperactivity disorder and substance use disorder
were present in approximately 34% of the visits. The most frequently prescribed
psychotropicmedicationsweremood stabilizers (64%) followed by antidepressants
(54%) and atypical antipsychotics (44%). Psychotherapy along with a psychotropic
medication was prescribed in about 1.81 million visits (30%). The most prescribed
combinations were psychotherapy along with mood stabilizers in 1.46 million vis-
its (24.12%) and psychotherapy along with atypical antipsychotics in 1.19 million
visits (19.6%). CONCLUSIONS: Less than one-third of the patients with bipolar dis-
order were prescribed psychotherapy in combination with pharmacotherapy as
recommended for treatment of bipolar disorders. More research is needed to eval-
uate the reasons for possible sub-optimal use of psychotherapy in bipolar disor-
ders.
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OBJECTIVES: To compare and identify the factors associated with persistence of
stimulant classes in children and adolescents with Attention-Deficit Hyperactivity
Disorder (ADHD).METHODS:A retrospective longitudinal cohort analysis was con-
ducted using the Medicaid Analytic eXtract data from 4 states - New York, Illinois,
Texas and California. ADHD patients, aged 6-18 years with at least one stimulant
prescription claim for a short-acting (SAS), intermediate-acting (IAS) or long-acting
stimulant (LAS) and one or more inpatient or outpatient claim involving a ADHD
diagnosis (ICD-9-CM code 314.xx) during the study period (January 2003 to Decem-
ber 2005) were selected. New stimulant users were defined as those with no previ-
ous stimulant drug prescription in the preceding 6 months. Additional criteria for
inclusion included 180 days of pre- and post-index continuous Medicaid eligibility
and no multiple index stimulant type claims. Persistence for the index stimulant
was measured by summing the number of days the patient remained on the index
stimulant therapy from the index prescription date with a maximum refill gap
between two consecutive index stimulant claims of 30 days. Stratified linear re-
gression modeling was used to determine the factors associated with persistence
for the three stimulant classes. RESULTS:Among the 63,362 ADHD patients (10,033
SAS, 5,061 IAS and 48,268 LAS users), LAS group had significantly longer mean and
median persistence (176 & 94 days), than the patients in SAS (102 & 60 days) or IAS
groups (57 & 95 days). Regression models revealed that race/ethnicity and recent
inpatient psychiatric treatment were negatively associated with stimulant persis-
tence in the three stimulant classes. Age (13 years) and addition of another psy-
chotropic medication, however, improved persistence significantly in all three
stimulant classes. CONCLUSIONS: Long acting stimulants had comparatively lon-
ger persistence than other stimulant classes. An understanding of demographic
and clinical characteristics that influence treatment continuation can help to im-
prove persistence rates in ADHD.
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OBJECTIVES: To examine the prevalence and time to psychotropic polypharmacy
in children with Attention-Deficit Hyperactivity Disorder (ADHD).METHODS: This
retrospective longitudinal database analysis of medical, pharmacy and eligibility
data was performed on Medicaid enrollees from four states – Texas, New York,
California, and Illinois – during a 3-year period (January 2003 and December 2005).
ADHD patients were identified on the basis of one or more ADHD diagnosis and
stimulant (short-acting [SAS], intermediate-acting [IAS] or long-acting [LAS]) pre-
scription(s). New stimulant users were selected if the index stimulant prescription
was filed between July 1, 2003 and June 30, 2005 with no previous stimulant drug
prescription in the preceding 6months. Additional eligibility criteria included con-
tinuous Medicaid eligibility 180 days pre- and post- index date and no multiple
index stimulant type claims. Psychotropic polypharmacy episode was defined as
30 consecutive days of non-stimulant therapy overlapping with the index stim-
ulant therapy. The time to psychotropic polypharmacywas assessed by calculating
the time from the index stimulant date to the first day of polypharmacy treatment
episode using the Cox proportional Hazards model. RESULTS: Among the 63,362
ADHD patients, 19.95% of SAS users, 24.26% of IAS users and 29.56% of LAS users
received combination pharmacotherapy involving their index stimulant. Median
survival time to psychotropic polypharmacywas found to be 299, 232, and 330 days
in the SAS, IAS and LAS treatment groups respectively. Recent inpatient psychiatric
visit(s) and younger age emerged as the common risk factors predicting index
stimulant and a psychotropic co-prescription. In addition, race/ethnicity and a
comorbidity of tics were also identified as predictors for LAS-related psychotropic
polypharmacy. CONCLUSIONS: Over one in five new stimulant users with ADHD
received a concomitant non-index stimulant prescription within a year of com-
mencing stimulant therapy. Demographic and clinical characteristics seem to play
a key role in psychotropic polypharmacy in children with ADHD.
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OBJECTIVES: Monotherapy with traditional mood stabilizers or atypical antipsy-
chotics is recommended as the first-line treatment for pediatric bipolar disorder.
This study examined the prescribing patterns of mood stabilizers and atypical
antipsychotics and adherence to these medications in children and adolescents
diagnosed with bipolar disorder. METHODS: 2003-2005 Medicaid Analytic eXtract
data of four states namely California, Illinois, Texas and NewYorkwas used. Study
participants were 6-18 years old, had a diagnosis of bipolar disorder, and had treat-
ment initiation with atypical antipsychotic ormood stabilizermonotherapy after a
6 month window without filling any of these medications. Descriptive statistics
was performed to observe the utilization pattern of monotherapy with mood sta-
bilizers and atypical antipsychotics. Medication possession ratio (MPR) was com-
pared between mood stabilizers and atypical antipsychotics during the 1 year pe-
riod after the treatment initiation. RESULTS: Out of 62,858 patients diagnosed
with bipolar disorder during the study period from 2003-05, there were a total of
14,946 patients who met inclusion criteria and whose treatment was initiated
with mood stabilizer or atypical antipsychotic monotherapy. Prescription of
atypical antipsychotics (73.36%) was predominantly higher than that of mood
stabilizers (26.64%). Among the atypical antipsychotics, the most frequently
prescribedmedication was risperidone (30%) followed by quetiapine (18.2%) and
olanzapine (14.4%). Among themood stabilizers, themost frequently prescribed
medication was oxcarbazepine (9.3%) followed by lithium (7.6% ) MPR for atyp-
ical antipsychotics was 0.82  0.18 and that of mood stabilizers was 0.81  0.19.
Almost 65% of the patients initiated on either of the medications were fully
adherent (MPR1). CONCLUSIONS: After receiving the recent US FDA approval for
the treatment of bipolar disorder in children and adolescents, atypical antipsychot-
ics are prescribed more frequently than traditional mood stabilizers, especially in
context of monotherapy. However, adherence to both the medication classes was
similar.
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OBJECTIVES: To compare the impact of various measures of adherence to antide-
pressant (AD) therapy on the estimation of the rate of depressive relapse using
claims database.METHODS: Using the Korean Health Insurance Review & Assess-
ment Service (HIRA) claims database (2006-2008), patients aged 18-84withoutmed-
ical visit due to depression (ICD 10F06.3, F31.3, F31.4, F32, F33, F34.1, F38.1, F41.2)
within 6 months before the first observed prescription of ADs between July 2006 to
Jun 2007 (18 months index period), and with at least 3 psychiatric visits within 3
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